Hepatobiliary Cancer Coverage from Every Angle


Radioactive Ablation for Liver Cancer: Focus on Patterns of Recurrence
How Many Patients With Hepatocellular Cancer Can Be Cured With Ablation?
Sex-Based Variations in Androgen Signaling Pathways in Patients With Liver Cancer
BRAF Variants and Therapeutic Direction in Intrahepatic Cholangiocarcinoma
Predicting Performance and Targets for Immunotherapy in Liver Cancer
Is Futibatinib of Benefit in Patients With FGFR2-Rearranged Intrahepatic Cholangiocarcinoma?
Financial Burden of Liver Cancer in the United States: A Need for Policy Interventions
Lenvatinib After Immunotherapy for Advanced Hepatocellular Carcinoma
TACE Plus Sorafenib for Patients With Liver Cancer and Portal Vein Tumor Thrombus
ASCO GI 2023: Adding Envafolimab to Lenvatinib Plus TACE in Unresectable Liver Cancer
ASCO GI 2023: Patient-Reported Outcomes With Lenvatinib Plus Pembrolizumab in Advanced Liver Cancer
ASCO GI 2023: Health-Related Quality-of-Life Outcomes With Tislelizumab Versus Sorafenib in Liver Cancer
ASCO GI 2023: Addition of Albumin-Bound Paclitaxel to Chemotherapy for Biliary Tract Cancers
ASCO GI 2023: Palliative Radiotherapy for Canadian Patients With Pain From Liver Cancer
ASCO GI 2023: Quadruplet Regimen Under Study in Advanced Biliary Tract Cancer
ASCO GI 2023: Phase III Study Combines SBRT and Sorafenib in Hepatocellular Carcinoma
Mutations in KRAS and ARID1a and the Growth of Bile Duct Cancer
Can Machine-Learning Models Predict Response to Treatment in Hepatocellular Carcinoma?
Preclinical Trial Sheds Light on Mechanisms of miR-22 Treatment in Liver Cancer
Is Progression of Liver Cancer Aided by Kupffer Cell–Induced CXCL5 Expression?
Sulfatases 1 and 2: Potential Therapeutic Targets in Intrahepatic Cholangiocarcinoma?
Can Methylated DNA Markers Outperform Cytology in the Diagnosis of Malignant Biliary Stricture?
AASLD 2022: Targeting Claudin-1 With a Monoclonal Antibody in Cholangiocarcinoma
Detecting Liver Cancer Via Genome-Wide Cell-Free Fragmentome Features
Second-Line Combination Chemotherapy Under Study in Biliary Tract Cancer
AASLD 2022: Novel Scoring System Assesses Risk of Liver Cancer in Certain Patients With HCV
SITC 2022: Ongoing Study of Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
AASLD 2022: Using MRI to Predict Response to Combination Immunotherapy for Liver Cancer
AASLD 2022: Updated U.S. Trends in Hepatocellular Carcinoma by Race and Ethnicity
ASTRO 2022: Real-Time Motion Monitoring in Identifying Liver Tumors
AASLD 2022: Comparing Performance of Blood Tests in Early-Stage Hepatocellular Carcinoma
AASLD 2022: Is Personalized Yttrium-90 Tumor Dose Predictive of Survival in Unresectable Liver Cancer?
ASTRO 2022: Can Adding Radiotherapy to Immunotherapy Improve Outcomes in Advanced Liver Cancer?
ASTRO 2022: Phase II Trial Compares TACE and SBRT in Hepatocellular Carcinoma
ASTRO 2022: Stereotactic Body Radiation Therapy Followed by Sorafenib Versus Sorafenib Alone in Liver Cancer
ASTRO 2022: Deep Learning–Based Framework in Liver Tumor Localization
Durvalumab Plus Tremelimumab Receives FDA Approval in Treatment of Advanced Liver Cancer
FDA Brief: Fast Track Designation Granted to STAT3 Inhibitor in Liver Cancer
Are Second- and Third-Generation U.S. Residents of Mexican Descent at Higher Risk for Liver Cancer?
Overall Survival Update on Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer
RATIONALE-301: Final Analysis Shows Benefit of Tislelizumab in Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma: Phase III Results Support Novel Doublet
FGFR2 Inhibitor Under Study in Cholangiocarcinoma
Phase III LEAP-002 Study of Lenvatinib Alone or With Pembrolizumab in Advanced Liver Cancer
FDA Brief: Futibatinib Granted Accelerated Approval in Intrahepatic Cholangiocarcinoma
Phase III COSMIC-312 Trial: Cabozantinib Plus Atezolizumab Versus Sorafenib in Advanced Liver Cancer
Best Practice Update From the AGA for Lean Individuals With Non-Alcoholic Fatty Liver Disease
Liver Transplantation for Patients With Hepatocellular Carcinoma: Long-Term Role of Downstaging
Adjuvant Radiotherapy After Surgery for Advanced Gallbladder Cancer
FDA Approves Durvalumab in Combination Regimen for Advanced or Metastatic Biliary Tract Cancer
Changing Trends in Incidence and Survival in Patients With Intrahepatic Cholangiocarcinoma
Perineural Invasion: Independent Predictor of Recurrence After Surgery for Intrahepatic Cholangiocarcinoma?
ESMO 2022: Second-Line Therapy for Advanced Biliary Cancer and Quality of Life
Immune Checkpoint and Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: Comparison of Toxicity Profiles
Immunotherapy for Advanced Biliary Tract Cancer: Tumor Mutational Burden as a Predictive Biomarker?
Predicting Liver Function Reserve Using Tomoelastography in Patients With Hepatocellular Carcinoma
Phase III LAUNCH Trial: Lenvatinib Plus TACE for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma in Sub-Saharan Africa: A Call for Improving Resources and Treatment
Durvalumab With and Without Tremelimumab in Unresectable Hepatocellular Carcinoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.